Zamann Pharma Support

Startseite
Deutschland
Lampertheim
Zamann Pharma Support

We from Zamann Pharma Support GmbH offer highest quality,
experience & consulting in the pharmaceutical area.

We are validation and support specialists of GxP processes and we provide comprehensive support for pharmaceutical companies.

23/07/2026

The Pentagon has officially classified WuXi AppTec as a “Chinese military company” – a step that could have far‑reaching consequences for the global pharma and biotech supply chain.

In our new article, we look at what this move really means for drug developers, CDMOs and investors: from heightened geopolitical risk to the urgency of diversifying away from single‑country manufacturing dependencies.

If your pipelines or portfolios touch China‑based development or manufacturing, this is a development you can’t afford to ignore.

Dive into the full analysis here:
https://zamann-pharma.com/2026/06/10/pentagon-labels-wuxi-apptec-military-linked-pharma-supply-chain-shock-intensifies/

21/07/2026

When the FDA blocks a core development path, the impact can be immediate and profound.

Our new article looks at how an FDA decision on a PRC2-targeted therapy led to the collapse of Fulcrum Therapeutics’ FSHD program and an 85% workforce reduction. We break down what happened, why the regulator took this stance, and what it could mean for future epigenetic and rare disease drug programs.

If you follow biotech, rare diseases, or drug development strategy, this is a case worth understanding in detail.

Read the full story here: https://zamann-pharma.com/2026/06/08/fda-blocks-prc2-drug-path-fulcrum-cuts-85-workforce-after-collapse/

16/07/2026

AI promises faster, smarter clinical trials – but right now, it’s also creating a serious trust and regulatory challenge.

From black‑box algorithms influencing patient selection to unanswered questions about validation, documentation and accountability, many teams are unsure how to use AI without putting trial integrity and compliance at risk.

Our latest article looks at why trust in AI for clinical trials is eroding, what regulators are signalling, and what sponsors and CROs can do today to introduce AI in a controlled, transparent and audit‑ready way.

Curious how to balance innovation with patient safety and regulatory expectations?
Read the full piece: https://zamann-pharma.com/2026/06/03/ai-in-clinical-trials-faces-trust-crisis-regulatory-uncertainty-grows/

14/07/2026

In pharma, we used to ask: "Is it fully validated?" Now we increasingly ask: "How fast can we adapt—without losing control?"

Our latest blog post looks at what really drove this shift from pure validation focus to a speed- and flexibility-driven mindset in pharma manufacturing. From new regulatory expectations (like Annex 1) to the impact of digital tools and better process data, we explain how companies can work faster and still stay fully compliant.

Curious how this affects your production, QA, or validation strategy?
👉 Read the full article here: https://zamann-pharma.com/2026/06/01/pharma-shifts-from-validation-to-speed-what-changed-behind-it/

09/07/2026

AstraZeneca and Roche are placing ever bigger bets on a more focused R&D strategy—especially in oncology. But as pipelines become more concentrated, an important question emerges: is overall failure risk rising, too?

In our new article, we look at how both companies are reshaping their portfolios, what this means for late‑stage risk exposure, and why focus can be both a strength and a vulnerability for big pharma.

If you’re interested in pharma strategy, R&D productivity, or biotech investing, this is a trend you’ll want to understand.

Read the full article here: https://zamann-pharma.com/2026/05/27/astrazeneca-and-roche-bet-on-focused-r-but-is-failure-risk-rising/

02/07/2026

In today’s GMP environment, data integrity is no longer a “nice to have” – it’s a core requirement for inspection readiness and sustainable compliance.

In our latest blog post, we break down:
• What regulators expect when it comes to data in GMP
• Why ALCOA+ is still essential – and what has changed
• Common data integrity findings during inspections
• How you can proactively prepare your systems, processes, and people

If you work in pharma, biotech, or any GxP-regulated area, this is a must-read to reduce inspection risk and strengthen your quality culture.

Dive into the full article here:
https://zamann-pharma.com/2026/05/20/data-in-gmp-in-year-data-integrity-compliance-requirements-and-inspection-readiness-explained/

30/06/2026

FDA expectations are evolving – and 2026 will be a turning point for pharma and biotech manufacturers.

AI is starting to reshape how inspections are planned and executed, how supply chains are monitored, and how quality teams demonstrate control of their processes and data.

If your compliance strategy still relies on siloed systems, manual checks, and static documentation, now is the time to rethink your approach.

In our latest blog post, we break down:
• How FDA compliance requirements are changing by 2026
• The role of AI in inspections and supply chain oversight
• What quality and regulatory teams can do today to get ready

Explore the key trends and practical actions here:
https://zamann-pharma.com/2026/05/18/are-you-ready-for-fda-compliance-changes-in-2026-ai-is-transforming-inspections-and-supply-chains/

25/06/2026

FDA and EMA just changed the rules for AI in pharma – and it’s going to impact how companies validate and operate AI systems in GxP environments.

Many organizations are still using traditional computer system validation (CSV) methods for AI/ML, but regulators now expect more:
• Ongoing monitoring of model performance
• Strong data governance and traceability
• Clear human oversight and decision control
• A lifecycle approach to AI validation, not a one‑time exercise

If your teams are working with AI in manufacturing, quality, clinical, or safety, this shift affects you.

We’ve summarized what’s new and what pharma companies should do next. Dive into the details and see how to future‑proof your AI compliance strategy:
https://zamann-pharma.com/2026/05/15/fda-and-ema-just-changed-ai-validation-rules-pharma-compliance-is-shifting-fast/

23/06/2026

GMP audits are no longer a once‑a‑year formality. They are a key tool for ensuring patient safety, regulatory compliance, and a strong quality culture.

In our latest article, we share a practical GMP audit checklist and highlight the most common findings – plus what you can do to avoid them and close gaps effectively.

If you work in pharma or biotech and want to strengthen your next inspection or internal audit, this is for you.

Read the full article here:
https://zamann-pharma.com/2026/05/14/pharmaceutical-audits-in-year-gmp-audit-checklist-and-findings/

18/06/2026

Are you ready for your next cGMP inspection?

Our new blog post looks at what inspectors are focusing on now, where companies most often fall short, and how you can proactively close critical compliance gaps.

From data integrity and documentation to quality culture and risk-based decision making, we highlight the key areas that can make or break your inspection outcome.

Dive into the full article here: https://zamann-pharma.com/2026/04/30/cgmp-in-year-inspection-expectations-and-compliance-gaps/

Adresse

SiedlerStr. 7
Lampertheim
68623

Webseite

https://zamann-pharma.com/shop

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Zamann Pharma Support erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.

Service Kontaktieren

Nachricht an Zamann Pharma Support senden:

Wollen Sie Ihr Service zum Top-Geschäft in Lampertheim machen?